No Data
No Data
Hisun Biomaterials Repurchases Shares Under 30 Million Yuan Buyback Scheme
Haizheng Life Sciences (688203.SH): Director Shen Xinghu resigns.
On August 28th, Hai Zheng Sheng Cai (688203.SH) announced that on August 28th, 2024, the board of directors received a written resignation report from Mr. Shen Xinghu, the Chairman of the Company. Due to personal reasons, Mr. Shen Xinghu requested to resign from the seventh board of directors, Chairman of the board of directors, member of the board of directors' audit committee, and convener of the board of directors' strategic committee, and no longer serve as the Company's legal representative. After resigning, Mr. Shen Xinghu will not hold any position in the Company.
Haizheng Shengcai (688203.SH) plans to spend 20 to 30 million yuan to repurchase shares.
Haizheng Biomaterials (688203.SH) announced that the company plans to repurchase some of the shares through centralized auction trading with its own funds...
Zhejiang Haizheng Biological Materials Co., Ltd. 2024 semi-annual report.
Zhejiang Haizheng Biotech Co., Ltd. Semi-annual Report Summary for 2024.
In the first half of the year, Hai Zheng Shengcai (688203.SH) had a net income of 25.1003 million yuan, an increase of 27.05% year-on-year.
On August 12th, Gelonhui reported that Haizhengshengcai (688203.SH) released its semi-annual report, with revenue of 0.431 billion yuan, a year-on-year increase of 29.19%, and a resin sales volume increase of 48.22%. Domestic sales increased by 35%, while overseas sales increased by 140%. In the first half of 2024, the net income attributable to the mother was 25.1003 million yuan, an increase of 27.05% year-on-year; the non-recurring net profit attributable to the mother was 20.99 million yuan, an increase of 19.04% year-on-year, mainly due to the increase in revenue and profit during the reporting period.
No Data
No Data